BACKGROUND/AIMS: Although chemotherapy in advanced pancreatic cancer procures dismal results, both 5-fluorouracil and gemcitabine have shown a modest activity. We report a phase II study of gemcitabine combined with protracted 5-fluorouracil. METHODOLOGY: Gemcitabine was given at 1000 mg/m2/week intravenously, in combination with concomitant 5-fluorouracil 200 mg/m2/day as a protracted venous infusion, both 3 out of 4 weeks in patients with locally advanced or metastatic pancreatic adenocarcinoma. Twenty-nine patients were enrolled, among whom 27 were metastatic. Response rate, overall and progression-free survival were endpoints, as well as tolerance and clinical benefit. RESULTS: We observed 3 (10%) partial responses, and 12 (42%) stabilizations within which the median disease control was 5.6 months. The median progression-free and overall survivals were 2.8 and 4 months, respectively. A clinical benefit was observed in 39% of patients. Myelosuppression was the main toxicity, but no grade 4 was observed. Other toxicities were mild. CONCLUSIONS: This combination chemotherapy was well tolerated in advanced pancreatic cancer patients.
BACKGROUND/AIMS: Although chemotherapy in advanced pancreatic cancer procures dismal results, both 5-fluorouracil and gemcitabine have shown a modest activity. We report a phase II study of gemcitabine combined with protracted 5-fluorouracil. METHODOLOGY:Gemcitabine was given at 1000 mg/m2/week intravenously, in combination with concomitant 5-fluorouracil 200 mg/m2/day as a protracted venous infusion, both 3 out of 4 weeks in patients with locally advanced or metastatic pancreatic adenocarcinoma. Twenty-nine patients were enrolled, among whom 27 were metastatic. Response rate, overall and progression-free survival were endpoints, as well as tolerance and clinical benefit. RESULTS: We observed 3 (10%) partial responses, and 12 (42%) stabilizations within which the median disease control was 5.6 months. The median progression-free and overall survivals were 2.8 and 4 months, respectively. A clinical benefit was observed in 39% of patients. Myelosuppression was the main toxicity, but no grade 4 was observed. Other toxicities were mild. CONCLUSIONS: This combination chemotherapy was well tolerated in advanced pancreatic cancerpatients.
Authors: Joan Maurel Santasusana; José Luis García López; Juan José García; Ana Isabel León Carbonero; Javier Gallego Plazas; Pedro Sánchez Rovira; Carlos Fernández Martos; M Carmen Galán Guzmán; Jesús Florián Jericó; Francisco Javier Dorta Delgado; Javier Casinello Espinosa; Marta Llanos Muñoz; Enrique Aranda Aguilar; Javier Sastre Valera; Ignacio García Ribas; Alfredo Carrato Mena Journal: Clin Transl Oncol Date: 2005-12 Impact factor: 3.405
Authors: Agustin A Garcia; Lawrence Leichman; Joaquina Baranda; Lalita Pandit; Heinz-Josef Lenz; Cynthia G Leichman Journal: Int J Gastrointest Cancer Date: 2003
Authors: Hanno Riess; Uwe Pelzer; Andreas Hilbig; Jens Stieler; Bernhard Opitz; Theo Scholten; Dörte Kauschat-Brüning; Peter Bramlage; Bernd Dörken; Helmut Oettle Journal: BMC Cancer Date: 2008-12-05 Impact factor: 4.430
Authors: F Di Costanzo; P Carlini; L Doni; B Massidda; R Mattioli; A Iop; E Barletta; L Moscetti; F Recchia; P Tralongo; S Gasperoni Journal: Br J Cancer Date: 2005-07-25 Impact factor: 7.640